More Positive Data For Recordati Cushing's Drug

Isturisa Could Become A Big Earner

With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.

Cushings Syndrome
Cushing’s affects approximately one to two patients per million per year • Source: Shutterstock

Three months after US approval and a couple of weeks after the European launch, Recordati Industria Chimica & Farmaceutica SPA has announced positive results from a major late-stage study confirming the effectiveness of its Cushing's disease therapy, Isturisa.

The Italian group has reported top-line data from the Phase III LINC-4 study evaluating Isturisa (osilodrostat) in 73 patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By 

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

More from Scrip

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.